22 Aug 2026
Innova Captab reopened its audited accounts for 2025-26 and approved revised standalone and consolidated results with a fresh auditor's report.
A deferred tax liability on fair value adjustments from the June 2023 acquisition of Sharon Bio-Medicine had never been recognised from the acquisition date. Consolidated profit for the year falls from Rs 143.18 crore to Rs 140.92 crore and earnings per share from 25.02 to 24.63, with the prior year down Rs 1.01 crore. There is no cash impact. A listed company reopening audited annual accounts is rare.